<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900665</url>
  </required_header>
  <id_info>
    <org_study_id>15136</org_study_id>
    <secondary_id>H8A-MC-LZAX</secondary_id>
    <nct_id>NCT01900665</nct_id>
  </id_info>
  <brief_title>Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo</brief_title>
  <acronym>EXPEDITION 3</acronym>
  <official_title>Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD)
      as compared with placebo in participants with mild AD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Solanezumab did not meet the study's primary endpoint.
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Activities Questionnaire (FAQ)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from financial management, shopping, playing games, food preparation, traveling, keeping appointments, keeping track of current events, and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. A negative change indicated an improvement from baseline. FAQ Total Score is the sum of 10 items, ranging from 0 (best possible outcome) to 100 (worst possible outcome). LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Assesses QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant's primary caregiver asked to complete same measure. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. Visual analog scale (VAS) assesses caregiver's impression of participant's health state; score ranges: 0 to 100 millimeter (mm). Lower scores=greater disease severity LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Integrated Alzheimer's Disease Rating Scale is used to assess that solanezumab slows down the cognitive and functional decline associated with AD compared with placebo. iADRS is a simple linear combination of ADAS-Cog 13 or 14 and the ADCS-iADL. The scale ranges from 0 to 146, where lower scores indicate worse performance. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants of Cognitive and Functional Responders</measure>
    <time_frame>Baseline through Week 80</time_frame>
    <description>Assess the proportion of participants who reach certain levels of cognitive and functional decline. Decline in cognition was defined as worsening from baseline by at least 6 or 9 points on the ADAS Cog14. If there is a cognitive decline of a specified cut-off or more at any time then the participant is considered a nonresponder. Functional nonresponders are participants who have not had any of the following at any time point: Clinically evident decline in ability to perform one or more basic ADL present at baseline; A clinically evident decline in ability to perform 20% or more of the instrumental ADL present at baseline; An increase in global CDR score of 1 point or more compared with baseline. A decline from no impairment to mild impairment (bADL, iADL is not considered clinically significant, but other declines of 1 or more points and any participant discontinuation within the first 6 months will be considered a non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Amyloid-Beta (Aβ) Species</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Concentration of amino acid peptide known as Aβ 1-42 in plasma. The change in plasma Aβ analytes after treatment were assessed separately for each plasma Aβ parameter. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>The vMRI assessment of right and left hippocampal atrophy, is reported. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)</measure>
    <time_frame>Visit 2 (Post-dose), Visit 5, 9, 15 (Pre-dose, Post-dose) and Visit 22 (Pre-dose): Pre-dose before the infusion, Post-dose 30 minutes End of Infusion</time_frame>
    <description>Area Under the Concentration versus Time Curve was evaluated for Solanezumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels</measure>
    <time_frame>Baseline, Week 80</time_frame>
    <description>Concentration of CSF parameters includes amino acid peptide known as Aβ 1-42 and Aβ 1-42. Analyses of these CSF biomarkers was conducted in a subset of participants (as an addendum to the protocol). The dependent variable for each CSF parameter was its change from baseline to endpoint. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2129</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Solanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solanezumab</intervention_name>
    <description>Administered Intravenously (IV)</description>
    <arm_group_label>Solanezumab</arm_group_label>
    <other_name>LY2062430</other_name>
    <other_name>A Beta Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets National Institute of Neurological and Communicative Disorders and
             Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
             for probable AD

          -  Has a Modified Hachinski Ischemia Scale score of less than or equal to 4

          -  Has a Mini-Mental State Examination (MMSE) score of 20 through 26 at Screening visit

          -  Has a Geriatric Depression Scale score of less than or equal to 6 (on the
             staff-administered short form)

          -  Has had a magnetic resonance imaging (MRI) or computerized tomography (CT) scan
             performed within the past 2 years that has confirmed no findings inconsistent with a
             diagnosis of AD

          -  Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
             result consistent with the presence of amyloid pathology at screening

        Exclusion Criteria:

          -  Does not have a reliable caregiver who is in frequent contact with the participant
             (defined as at least 10 hours per week), will accompany the participant to the office
             and/or be available by telephone at designated times, and will monitor administration
             of prescribed medications

          -  Meets National Institute of Neurological Disorders and Stroke/Association
             Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN)
             criteria for vascular dementia

          -  Has current serious or unstable illnesses including cardiovascular, hepatic, renal,
             gastroenterologic, respiratory, endocrinologic, neurologic (other than AD),
             psychiatric, immunologic, or hematologic disease and other conditions that, in the
             investigator's opinion, could interfere with the analyses of safety and efficacy in
             this study; or has a life expectancy of &lt;2 years

          -  Has had a history within the last 5 years of a serious infectious disease affecting
             the brain or head trauma resulting in protracted loss of consciousness

          -  Has a history within the last 5 years of a primary or recurrent malignant disease with
             the exception of resected cutaneous squamous cell carcinoma in situ, basal cell
             carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal
             prostate-specific antigen posttreatment

          -  Has a known history of human immunodeficiency virus (HIV), clinically significant
             multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions

          -  Has received acetylcholinesterase inhibitor (AChEIs), memantine and/or other AD
             therapy for less than 4 months or has less than 2 months of stable therapy on these
             treatments

          -  Has received medications that affect the central nervous system (CNS), except
             treatments for AD, for less than 4 weeks

          -  Has a history of chronic alcohol or drug abuse/dependence within the past 5 years

          -  Has a Visit 1 MRI with results showing &gt;4 Amyloid-related Imaging Abnormality (ARIA),
             -hemorrhage /hemosiderin deposition (ARIA-H) or presence of ARIA-E (edema/effusions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Josephs Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANI Arizona Neurological Institute Research, PC</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Neuropsychiatric Research Institute, Inc</name>
      <address>
        <city>Carson</city>
        <state>California</state>
        <zip>90746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Memory Impairment &amp; Neurological Disorders</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Clinical Trials, Inc.</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network - CNS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apostle Clinical Trials, Inc</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Southern California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Neuroscience Medical Group</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Mesa Vista Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research Institute</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center for Clinical Studies</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Research Institute</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohen Medical Associates P.A.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research . LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic of Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Home and Hospital for the Aged</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinical Research, Inc</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351-6637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Alzheimer's Disease Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTT Consultants</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Physician's Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Office: J. Gary Booker</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Neurology</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmaSite Research Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Nebraska Med Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Radiology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvanceMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neurosciences</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials, LLC.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavorial Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Center Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guilford Neurologic Associates</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Research</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ College Of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insight Clinical Trials</name>
      <address>
        <city>Shaker Heights</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red River Medical Center, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Corvallis Clinic P.C.</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network Inc</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine at EPPI</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Psychiatry Associates Avera Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quillen College of Medicine, East TN State University</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Research Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>East Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Caulfield</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>06008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1N 5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boeblingen</city>
        <zip>71034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponderano (BI)</city>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>474-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>670-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaraki</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobe</city>
        <zip>655-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>616-8255</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-8636</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Katowice</city>
        <zip>40-588</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sopot</city>
        <zip>81-824</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-813</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guipuzcoa</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plasencia</city>
        <zip>10600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt-Girona</city>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmo</city>
        <zip>212 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Molndal</city>
        <zip>431 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Umea</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <state>Avon</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Crowborough</city>
        <state>East Sussex</state>
        <zip>TN6 1HB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scotland</city>
        <state>Glasgow</state>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greater London</city>
        <state>London</state>
        <zip>W1G9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Swindon</city>
        <state>Wiltshire</state>
        <zip>SN3 6BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>February 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2018</results_first_posted>
  <disposition_first_submitted>December 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 23, 2016</disposition_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were excluded after study enrollment,if PET imaging or CSF results did not show evidence of brain amyloid pathology,a screening MRI with results &gt;4 ARIA-H(amyloid-related imaging abnormality-hemorrhage/hemosiderin deposition) or presence of ARIA-E(amyloid-related imaging abnormality-edema/effusions) and abnormal lab results were found.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Solanezumab</title>
          <description>Participants received Solanezumab 400 milligrams (mg)Intravenously (IV) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo Controlled Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1057"/>
                <participants group_id="P2" count="1072"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1054"/>
                <participants group_id="P2" count="1067"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="914"/>
                <participants group_id="P2" count="908"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="881">Patients from Placebo Controlled Period were not required to enter into Open Label Period.</participants>
                <participants group_id="P2" count="859">Patients from Placebo Controlled Period were not required to enter into Open Label Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="881"/>
                <participants group_id="P2" count="859"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent/Caregiver Decision</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="802"/>
                <participants group_id="P2" count="765"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Solanezumab</title>
          <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
Placebo: Administered IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1057"/>
            <count group_id="B2" value="1072"/>
            <count group_id="B3" value="2129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.69" spread="7.814"/>
                    <measurement group_id="B2" value="73.26" spread="7.966"/>
                    <measurement group_id="B3" value="72.98" spread="7.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="600"/>
                    <measurement group_id="B2" value="631"/>
                    <measurement group_id="B3" value="1231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>All randomized participants who had baseline ethnicity data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="970"/>
                    <count group_id="B2" value="986"/>
                    <count group_id="B3" value="1956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="921"/>
                    <measurement group_id="B2" value="937"/>
                    <measurement group_id="B3" value="1858"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>All randomized participants who had baseline race data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="970"/>
                    <count group_id="B2" value="986"/>
                    <count group_id="B3" value="1956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="878"/>
                    <measurement group_id="B2" value="894"/>
                    <measurement group_id="B3" value="1772"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="537"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1057"/>
                    <count group_id="B2" value="1072"/>
                    <count group_id="B3" value="2129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)</title>
        <description>The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)</title>
          <description>The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1053"/>
                <count group_id="O2" value="1067"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="0.355"/>
                    <measurement group_id="O2" value="7.44" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>The Kenward-Roger approximation was used to estimate the denominator degrees of freedom.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)</title>
        <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant’s caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)</title>
          <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant’s caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="896"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.17" spread="0.318"/>
                    <measurement group_id="O2" value="-7.17" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)</title>
        <description>The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer’s disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)</title>
          <description>The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer’s disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1053"/>
                <count group_id="O2" value="1067"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="0.284"/>
                    <measurement group_id="O2" value="5.90" spread="0.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE)</title>
        <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE)</title>
          <description>MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="893"/>
                <count group_id="O2" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="0.154"/>
                    <measurement group_id="O2" value="-3.66" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)</title>
        <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant’s caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)</title>
          <description>The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant’s caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.42" spread="0.386"/>
                    <measurement group_id="O2" value="-8.77" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Activities Questionnaire (FAQ)</title>
        <description>FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant’s ability to perform a variety of activities ranging from financial management, shopping, playing games, food preparation, traveling, keeping appointments, keeping track of current events, and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. A negative change indicated an improvement from baseline. FAQ Total Score is the sum of 10 items, ranging from 0 (best possible outcome) to 100 (worst possible outcome). LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Activities Questionnaire (FAQ)</title>
          <description>FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant’s ability to perform a variety of activities ranging from financial management, shopping, playing games, food preparation, traveling, keeping appointments, keeping track of current events, and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. A negative change indicated an improvement from baseline. FAQ Total Score is the sum of 10 items, ranging from 0 (best possible outcome) to 100 (worst possible outcome). LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="907"/>
                <count group_id="O2" value="892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="0.212"/>
                    <measurement group_id="O2" value="5.57" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)</title>
        <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)</title>
          <description>CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="2.442"/>
                    <measurement group_id="O2" value="2.23" spread="2.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropsychiatric Inventory (NPI)</title>
        <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant’s behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropsychiatric Inventory (NPI)</title>
          <description>NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant’s behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="3.11"/>
                    <measurement group_id="O2" value="0.382" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)</title>
        <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
Placebo: Administered IV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)</title>
          <description>Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Number of hospitalizations</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="891"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basic ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.058"/>
                    <measurement group_id="O2" value="0.35" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instrumental ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.099"/>
                    <measurement group_id="O2" value="0.50" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sum of Basic and Instrumental ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.132"/>
                    <measurement group_id="O2" value="0.86" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supervision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.125"/>
                    <measurement group_id="O2" value="0.88" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)</title>
        <description>Assesses QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant’s primary caregiver asked to complete same measure. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)</title>
          <description>Assesses QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant’s primary caregiver asked to complete same measure. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="853"/>
                <count group_id="O2" value="812"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.158"/>
                    <measurement group_id="O2" value="-0.72" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)</title>
        <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. Visual analog scale (VAS) assesses caregiver's impression of participant's health state; score ranges: 0 to 100 millimeter (mm). Lower scores=greater disease severity LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)</title>
          <description>EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. Visual analog scale (VAS) assesses caregiver's impression of participant's health state; score ranges: 0 to 100 millimeter (mm). Lower scores=greater disease severity LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="904"/>
                <count group_id="O2" value="892"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.556"/>
                    <measurement group_id="O2" value="-2.61" spread="0.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Integrated Alzheimer’s Disease Rating Scale (iADRS)</title>
        <description>Integrated Alzheimer’s Disease Rating Scale is used to assess that solanezumab slows down the cognitive and functional decline associated with AD compared with placebo. iADRS is a simple linear combination of ADAS-Cog 13 or 14 and the ADCS-iADL. The scale ranges from 0 to 146, where lower scores indicate worse performance. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Integrated Alzheimer’s Disease Rating Scale (iADRS)</title>
          <description>Integrated Alzheimer’s Disease Rating Scale is used to assess that solanezumab slows down the cognitive and functional decline associated with AD compared with placebo. iADRS is a simple linear combination of ADAS-Cog 13 or 14 and the ADCS-iADL. The scale ranges from 0 to 146, where lower scores indicate worse performance. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="883"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.92" spread="0.533"/>
                    <measurement group_id="O2" value="-14.59" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants of Cognitive and Functional Responders</title>
        <description>Assess the proportion of participants who reach certain levels of cognitive and functional decline. Decline in cognition was defined as worsening from baseline by at least 6 or 9 points on the ADAS Cog14. If there is a cognitive decline of a specified cut-off or more at any time then the participant is considered a nonresponder. Functional nonresponders are participants who have not had any of the following at any time point: Clinically evident decline in ability to perform one or more basic ADL present at baseline; A clinically evident decline in ability to perform 20% or more of the instrumental ADL present at baseline; An increase in global CDR score of 1 point or more compared with baseline. A decline from no impairment to mild impairment (bADL, iADL is not considered clinically significant, but other declines of 1 or more points and any participant discontinuation within the first 6 months will be considered a non-responder.</description>
        <time_frame>Baseline through Week 80</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants of Cognitive and Functional Responders</title>
          <description>Assess the proportion of participants who reach certain levels of cognitive and functional decline. Decline in cognition was defined as worsening from baseline by at least 6 or 9 points on the ADAS Cog14. If there is a cognitive decline of a specified cut-off or more at any time then the participant is considered a nonresponder. Functional nonresponders are participants who have not had any of the following at any time point: Clinically evident decline in ability to perform one or more basic ADL present at baseline; A clinically evident decline in ability to perform 20% or more of the instrumental ADL present at baseline; An increase in global CDR score of 1 point or more compared with baseline. A decline from no impairment to mild impairment (bADL, iADL is not considered clinically significant, but other declines of 1 or more points and any participant discontinuation within the first 6 months will be considered a non-responder.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1057"/>
                <count group_id="O2" value="1072"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive Responders: Cut-off 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Responders: Cut-off 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functional Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Amyloid-Beta (Aβ) Species</title>
        <description>Concentration of amino acid peptide known as Aβ 1-42 in plasma. The change in plasma Aβ analytes after treatment were assessed separately for each plasma Aβ parameter. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Amyloid-Beta (Aβ) Species</title>
          <description>Concentration of amino acid peptide known as Aβ 1-42 in plasma. The change in plasma Aβ analytes after treatment were assessed separately for each plasma Aβ parameter. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants.</population>
          <units>Picogram/milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1057"/>
                <count group_id="O2" value="1072"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Modified amyloid beta 1-40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="841"/>
                    <count group_id="O2" value="842"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172754.36" spread="1613.534"/>
                    <measurement group_id="O2" value="262.98" spread="1609.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified amyloid beta1-42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="848"/>
                    <count group_id="O2" value="840"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18485.26" spread="104.913"/>
                    <measurement group_id="O2" value="15.75" spread="105.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)</title>
        <description>The vMRI assessment of right and left hippocampal atrophy, is reported. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)</title>
          <description>The vMRI assessment of right and left hippocampal atrophy, is reported. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants.</population>
          <units>Cubic millimeter (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1057"/>
                <count group_id="O2" value="1072"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right hippocampal atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-145.7" spread="75.42"/>
                    <measurement group_id="O2" value="-154.1" spread="81.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left hippocampal atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-142.3" spread="74.27"/>
                    <measurement group_id="O2" value="-146.3" spread="78.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right hippocampal atrophy+Left hippocampal atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-288.0" spread="135.19"/>
                    <measurement group_id="O2" value="-300.4" spread="138.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right entorhinal cortex atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.3" spread="45.18"/>
                    <measurement group_id="O2" value="-80.8" spread="45.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left entorhinal cortex atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-91.6" spread="47.60"/>
                    <measurement group_id="O2" value="-95.2" spread="53.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right+Left entorhinal cortex atrophy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="789"/>
                    <count group_id="O2" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-169.0" spread="79.65"/>
                    <measurement group_id="O2" value="-176.0" spread="86.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrophy of whole brain volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="786"/>
                    <count group_id="O2" value="769"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22725.6" spread="11920.78"/>
                    <measurement group_id="O2" value="-23500.5" spread="12000.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enlargement of Ventricular volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="788"/>
                    <count group_id="O2" value="770"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7055.4" spread="4580.36"/>
                    <measurement group_id="O2" value="7226.6" spread="4545.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)</title>
        <description>Area Under the Concentration versus Time Curve was evaluated for Solanezumab.</description>
        <time_frame>Visit 2 (Post-dose), Visit 5, 9, 15 (Pre-dose, Post-dose) and Visit 22 (Pre-dose): Pre-dose before the infusion, Post-dose 30 minutes End of Infusion</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication (Solanezumab) with evaluable Solanezumab PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)</title>
          <description>Area Under the Concentration versus Time Curve was evaluated for Solanezumab.</description>
          <population>All randomized participants who received at least 1 dose of study medication (Solanezumab) with evaluable Solanezumab PK data.</population>
          <units>milligram*hour per milliliter (mg*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1044"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan</title>
        <description>Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan</title>
          <description>Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>standard uptake value ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="915"/>
                <count group_id="O2" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject specific white matter corrected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="805"/>
                    <count group_id="O2" value="791"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.002"/>
                    <measurement group_id="O2" value="0.02" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean whole cerebellum corrected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="805"/>
                    <count group_id="O2" value="791"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.005"/>
                    <measurement group_id="O2" value="0.00" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels</title>
        <description>Concentration of CSF parameters includes amino acid peptide known as Aβ 1-42 and Aβ 1-42. Analyses of these CSF biomarkers was conducted in a subset of participants (as an addendum to the protocol). The dependent variable for each CSF parameter was its change from baseline to endpoint. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
        <time_frame>Baseline, Week 80</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels</title>
          <description>Concentration of CSF parameters includes amino acid peptide known as Aβ 1-42 and Aβ 1-42. Analyses of these CSF biomarkers was conducted in a subset of participants (as an addendum to the protocol). The dependent variable for each CSF parameter was its change from baseline to endpoint. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.</population>
          <units>picogram/milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1057"/>
                <count group_id="O2" value="1072"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free amyloid beta 1-42, CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.33" spread="7.507"/>
                    <measurement group_id="O2" value="-9.27" spread="8.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Modified amyloid beta 1-42, CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.69" spread="42.620"/>
                    <measurement group_id="O2" value="-107.91" spread="42.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up To 80 Weeks</time_frame>
      <desc>All randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Solanezumab: Double-Blind Phase</title>
          <description>Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Double-Blind Phase</title>
          <description>Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Solanezumab: Open Label</title>
          <description>Participants who complete 80 weeks treatment/assessment of the double-blind period were entered into open-label period. Participants received Solanezumab 400 mg IV every 4 weeks for 180 weeks with an additional 4 weeks of assessments.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Open Label</title>
          <description>Participants who complete 80 weeks treatment/assessment of the double-blind period were entered into open-label period. Participants received Placebo IV every 4 weeks for 180 weeks with an additional 4 weeks of assessments.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="1054"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="1067"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="879"/>
                <counts group_id="E4" subjects_affected="114" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Adams-stokes syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1054"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1067"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="879"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1054"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Paraspinal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1054"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1067"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Coronary vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="1054"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="1067"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="879"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1054"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1067"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1054"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1067"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Troponin t increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Benign small intestinal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="599"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="599"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of renal pelvis and ureter metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="599"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="627"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dementia of the alzheimer's type, with delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Spinal epidural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="1054"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="1067"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="879"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Tonic convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalhaematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Behavioural and psychiatric symptoms of dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Phobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1054"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="599"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="627"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pharyngeal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1054"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Immobilisation prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Respite care</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1067"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1054"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1067"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="879"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="536" subjects_at_risk="1054"/>
                <counts group_id="E2" subjects_affected="530" subjects_at_risk="1067"/>
                <counts group_id="E3" subjects_affected="255" subjects_at_risk="879"/>
                <counts group_id="E4" subjects_affected="260" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="86" subjects_affected="76" subjects_at_risk="1054"/>
                <counts group_id="E2" events="109" subjects_affected="87" subjects_at_risk="1067"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="879"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="69" subjects_affected="54" subjects_at_risk="1054"/>
                <counts group_id="E2" events="63" subjects_affected="46" subjects_at_risk="1067"/>
                <counts group_id="E3" events="32" subjects_affected="23" subjects_at_risk="879"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="114" subjects_affected="89" subjects_at_risk="1054"/>
                <counts group_id="E2" events="99" subjects_affected="80" subjects_at_risk="1067"/>
                <counts group_id="E3" events="31" subjects_affected="29" subjects_at_risk="879"/>
                <counts group_id="E4" events="36" subjects_affected="32" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="64" subjects_at_risk="1054"/>
                <counts group_id="E2" events="61" subjects_affected="54" subjects_at_risk="1067"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="879"/>
                <counts group_id="E4" events="23" subjects_affected="21" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="79" subjects_affected="58" subjects_at_risk="1054"/>
                <counts group_id="E2" events="103" subjects_affected="72" subjects_at_risk="1067"/>
                <counts group_id="E3" events="47" subjects_affected="38" subjects_at_risk="879"/>
                <counts group_id="E4" events="46" subjects_affected="36" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="195" subjects_affected="146" subjects_at_risk="1054"/>
                <counts group_id="E2" events="207" subjects_affected="144" subjects_at_risk="1067"/>
                <counts group_id="E3" events="97" subjects_affected="67" subjects_at_risk="879"/>
                <counts group_id="E4" events="109" subjects_affected="80" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="44" subjects_at_risk="1054"/>
                <counts group_id="E2" events="62" subjects_affected="56" subjects_at_risk="1067"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="879"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="70" subjects_affected="63" subjects_at_risk="1054"/>
                <counts group_id="E2" events="67" subjects_affected="60" subjects_at_risk="1067"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="879"/>
                <counts group_id="E4" events="23" subjects_affected="23" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="66" subjects_affected="61" subjects_at_risk="1054"/>
                <counts group_id="E2" events="65" subjects_affected="57" subjects_at_risk="1067"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="879"/>
                <counts group_id="E4" events="31" subjects_affected="29" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="96" subjects_affected="86" subjects_at_risk="1054"/>
                <counts group_id="E2" events="151" subjects_affected="86" subjects_at_risk="1067"/>
                <counts group_id="E3" events="34" subjects_affected="28" subjects_at_risk="879"/>
                <counts group_id="E4" events="42" subjects_affected="29" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="57" subjects_affected="54" subjects_at_risk="1054"/>
                <counts group_id="E2" events="59" subjects_affected="58" subjects_at_risk="1067"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="879"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="856"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="62" subjects_affected="60" subjects_at_risk="1054"/>
                <counts group_id="E2" events="57" subjects_affected="57" subjects_at_risk="1067"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="879"/>
                <counts group_id="E4" events="20" subjects_affected="20" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="53" subjects_affected="44" subjects_at_risk="1054"/>
                <counts group_id="E2" events="69" subjects_affected="58" subjects_at_risk="1067"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="879"/>
                <counts group_id="E4" events="22" subjects_affected="18" subjects_at_risk="856"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

